Bol, J.M. van der

irinotecan patient cancer pharmacokinetic jessica neutropenia bw.indd 29-04-11 effect -38 treatment study sn -38 clearance metabolite group smoking verweij j toxicity creatinine clearance function polymorphism jong fa mathijssen rh omeprazole chapter irinotecan treatment sn -38g mathijssen level smoker creatinine methimazole dosing cancer patients cyp 3a toxicitie verweij genotype grade exposure diarrhea irinotecan-induced factor ugt 1a incidence analysis result bedankt figure colorectal bedankt voor bruijn p table oncol transporter metabolism pharmacol enzyme cigarette inhibitor interaction loos wj variability 350 mg /m promoter plasma irinotecan pharmacokinetics blood influence metabolite sn -38 addition range colorectal cancer concentration metastatic colorectal cancer jullie allele ethyl jonge mj